Le Monde Diplomatique Global funding for developing countries from public-private partnerships, especially vaccine and drug manufacturers, quadrupled between 2000 and 2007; between 2001 and 2010 it tripled, reaching $28.2bn in 2010. ... than for reasons of national security ...
Reuters China is an increasingly important country for international drugmakers such as GSK, which are relying on growth in emerging markets to offset slower sales in Western markets where many former top-selling medicines have lost patent protection. IMS ...
The Herald | HeraldOnline.com Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we ... Building on the pioneering work of scientific founder and Nobel ...
Reuters However, new product introductions and strong growth in emerging markets are helping to mitigate the industry factors that are dampening growth . BSX's IC has declined 15% during the LTM period ended March 31, 2013, largely driven by heightened ... and more »
Nanowerk Patients treated with Herceptin, a monoclonal antibody that targets a growth promoting factor common to breast cancers (Her2), often relapse as their tumors become resistant to the drug . overcoming camptothecin”s toxicity and low solubility represent ...
The Guardian The growth of antibiotic-resistant infections represents a "looming public health issue" for Australia that requires "urgent" new funding to prevent deaths from minor ailments such as sore throats and cut knees, the country's top scientist has warned ... and more »
Nursing Times The research also points to stress, and the body's response to it, being a possible risk factor for prostate cancer. In addition it indicates a potential new treatment pathway involving drugs such as beta-blockers, already used to lower blood pressure ... and more »
New York Times (blog) When Onyx Pharmaceuticals, a cancer drug developer, turned down a $10 billion acquisition bid by Amgen last month and put itself up for sale, its share price soared more than 50 percent, touching off an investor frenzy in biotechnology. Among the ... and more »
Medical Daily The drug targets growth factor receptors that are present on cancer cells, blocking their function. Gilotrif is also being investigated in a variety of...
